Health
Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®
TORONTO & BENGALURU, India, April 21, 2026--Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.
About this update from Biocon Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3075,"height":1275,"url":"https://media.zenfs.com/en/business-wire.com/f6df8d0ee608504dfcc95a2bd31ce9b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KuZJm2H3rt0A78kUiRsBvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5OA--/https://media.zenfs.com/en/business-wire.com/f6df8d0ee608504dfcc95a2bd31ce9b2","width":960,"height":398},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MAsgrXLohbbzySgRb6zfSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05OTY-/https://media.zenfs.com/en/business-wire.com/f6df8d0ee608504dfcc95a2bd31ce9b2","width":1200,"height":498}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer","length":162,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":237,"olType":false},{"type":"text","content":"TORONTO & BENGALURU, India, April 21, 2026--(BUSINESS WIRE)--Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for Bosaya™ (denosumab), a biosimilar to Prolia®, and Vezuo™ (denosumab), a biosimilar to Xgeva®, on April 3, 2026. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.","length":596,"tagName":"p"},{"type":"text","content":"Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.","length":154,"tagName":"p"},{"type":"text","content":"Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, "Health Canada’s approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high‑quality biosimilars in key global markets. This approval reflects our strong scientific and regulat...